
    
      Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory
      blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female
      subjects. The study consisted in 2 periods separated by a wash-out of at least 7 days between
      doses. To demonstrate the bioequivalence (BE) between two active product ingredient (API)
      sources [current API source - marketed formulation (MF) versus new API source -
      to-be-marketed (TBM)] of eslicarbazepine acetate (ESL)
    
  